Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
AI use in schools: How districts are making sure it's used as a study aid
Recommended
The sun now sets before 8 p.m. Will we ever do away with the time change?
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Prometheus Biosciences Inc
(NQ:
RXDX
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Jun 15, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Prometheus Biosciences Inc
< Previous
1
2
3
4
5
Next >
Why Is Prometheus Biosciences (RXDX) Stock Up 175% Today?
December 07, 2022
Prometheus Biosciences (NASDAQ:RXDX) stock is rocketing higher on Wednesday after reporting results from two Phase 2 clinical trials.
Via
InvestorPlace
Prometheus Biosciences Catapults 176% On Promising Results In Irritable Bowel Disease
December 07, 2022
Prometheus Biosciences made waves Wednesday in irritable bowel disease.
Via
Investor's Business Daily
These 2 Nasdaq Stocks Knocked It Out of the Park Wednesday
December 07, 2022
Even as broader markets fell, these companies announced great news.
Via
The Motley Fool
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
December 07, 2022
Via
Benzinga
Prometheus Biosciences Stock Skyrockets After Favorable Data From Ulcerative Colitis, Crohn's Disease Studies
December 07, 2022
Via
Benzinga
Prometheus Biosciences Announces Positive Results for PRA023 in Both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a Studies Enabling Pathway to Both First-in-Class and Best-in-Class Anti-TL1A mAb
December 07, 2022
From
Prometheus Biosciences
Via
GlobeNewswire
Why Shares of Prometheus Biosciences Slumped This Week
December 02, 2022
The company's lead pipeline candidate is facing competition from a Pfizer-backed drug.
Via
The Motley Fool
Prometheus Biosciences Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress
November 09, 2022
From
Prometheus Biosciences
Via
GlobeNewswire
Prometheus Biosciences to Participate at November Healthcare Conferences
November 01, 2022
From
Prometheus Biosciences
Via
GlobeNewswire
Oppenheimer Maintains Outperform Rating for Prometheus Biosciences: Here's What You Need To Know
October 04, 2022
Oppenheimer has decided to maintain its Outperform rating of Prometheus Biosciences (NASDAQ:RXDX) and raise its price target from $50.00 to $65.00. Shares of Prometheus Biosciences are trading down...
Via
Benzinga
Where Prometheus Biosciences Stands With Analysts
October 04, 2022
Over the past 3 months, 7 analysts have published their opinion on Prometheus Biosciences (NASDAQ:RXDX) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
Expert Ratings for Prometheus Biosciences
August 29, 2022
Within the last quarter, Prometheus Biosciences (NASDAQ:RXDX) has observed the following analyst ratings:
Via
Benzinga
Analyst Ratings for Prometheus Biosciences
August 29, 2022
Analysts have provided the following ratings for Prometheus Biosciences (NASDAQ:RXDX) within the last quarter:
Via
Benzinga
Analyst Ratings for Prometheus Biosciences
May 13, 2022
Analysts have provided the following ratings for Prometheus Biosciences (NASDAQ:RXDX) within the last quarter:
Via
Benzinga
Delta Air Lines To Rally Around 84%? Here Are 5 Other Price Target Changes For Tuesday
October 04, 2022
Raymond James raised Delta Air Lines, Inc. (NYSE: DAL) price target from $50 to $52. Raymond James analyst Savanthi Syth maintained a Strong Buy rating on the stock. Delta Air shares rose 0.7% to close...
Via
Benzinga
Prometheus Biosciences Receives FDA Clearance of IND Application for its Second Precision Program, PRA052
October 03, 2022
From
Prometheus Biosciences
Via
GlobeNewswire
7 Top-Rated Biotech Stocks to Buy for Q4
September 15, 2022
A new White House program makes these seven names some outstanding biotech stocks to buy for the fourth quarter.
Via
InvestorPlace
15 Biotech Stocks That Hit Year Highs Over The Last Week, Including Sarepta, Axsome
August 30, 2022
Not all shares are slowing down alongside the industry group.
Via
Investor's Business Daily
SVB Leerink Slashes Price Target On This Stock By Over 73%, Plus This Analyst Predicts $56 For Toll Brothers
August 29, 2022
Citigroup raised the price target for MacroGenics, Inc. (NASDAQ: MGNX) from $13 to $16. MacroGenics shares rose 4.8% to $3.90 in pre-market trading.
Via
Benzinga
Ulta Beauty To $511? Here Are 5 Other Price Target Changes For Monday
August 29, 2022
Barclays boosted the price target on Ulta Beauty, Inc. (NASDAQ: ULTA) from $491 to $511. Barclays analyst Adrienne Yih maintained an Overweight rating on the stock. Ulta Beauty shares fell 1% to...
Via
Benzinga
Where Prometheus Biosciences Stands With Analysts
August 12, 2022
Over the past 3 months, 4 analysts have published their opinion on Prometheus Biosciences (NASDAQ:RXDX) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
Recap of Monday's Biotech Catalysts - End of the Day Summary
July 18, 2022
Abbvie (NYSE: ABBV) has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for atogepant for the prophylaxis of migraine in adult patients who have at least...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2022
July 20, 2022
Upgrades
Via
Benzinga
Prometheus Biosciences Stock Shows Rising Relative Strength
July 14, 2022
Prometheus Biosciences stock saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, with an increase from 72 to 90.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For June 10, 2022
June 10, 2022
Via
Benzinga
10 Biggest Price Target Changes For Thursday
March 10, 2022
Keybanc cut the price target on Asana, Inc. (NYSE: ASAN) from $97 to $61. Asana shares fell 23.6% to $37.29 in pre-market trading.
Via
Benzinga
Analyst Ratings For Prometheus Biosciences
February 11, 2022
Analysts have provided the following ratings for Prometheus Biosciences (NASDAQ:RXDX) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish...
Via
Benzinga
Expert Ratings For Prometheus Biosciences
February 11, 2022
Over the past 3 months, 6 analysts have published their opinion on Prometheus Biosciences (NASDAQ:RXDX) stock. These analysts are typically employed by large Wall Street banks and...
Via
Benzinga
52 Biggest Movers From Friday
January 18, 2022
Gainers Splash Beverage Group, Inc. (NASDAQ: SBEV) shares gained 118.9% to settle at $4.18 on Friday. Splash Beverage recently announced it has received authorization to sell its...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 13, 2021
December 13, 2021
Upgrades According to B of A Securities, the prior rating for Globus Medical Inc (NYSE:
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.